Welcome to our dedicated page for Alcon news (Ticker: ALC), a resource for investors and traders seeking the latest updates and insights on Alcon stock.
Alcon Inc. (ALC) generates frequent news as a global eye care company listed on the SIX Swiss Exchange and the New York Stock Exchange. Company communications emphasize a long heritage in eye care, a broad Surgical and Vision Care portfolio, and a large international patient reach, which together make Alcon a regular subject of healthcare, medical device and capital markets coverage.
News about Alcon often highlights developments in its Surgical and Vision Care segments, including product launches and portfolio updates that address conditions such as cataracts, glaucoma, retinal diseases and refractive errors. The company has stated that it is advancing global launches of major products across these franchises, and such initiatives are typically announced through press releases and investor events.
Investors following ALC news can also expect updates on corporate strategy and transactions. For example, Alcon has reported on a definitive merger agreement with STAAR Surgical Company and later announced the termination of that agreement in a January 6, 2026 press release. These items appear in both company news and related regulatory filings, providing insight into how Alcon approaches acquisitions and refractive surgery strategy.
Coverage may further include Alcon’s participation in major healthcare conferences, where senior executives present the company’s outlook and discuss its Surgical and Vision Care businesses. Such events are typically accompanied by webcasts and formal announcements. By monitoring this news feed, readers can track key developments affecting Alcon’s product portfolio, strategic direction and presence in the global eye care market.
Alcon Inc. ('ALC') has launched a private offering of US$700 million in 5.375% senior notes due 2032 and US$600 million in 5.750% senior notes due 2052. The offering is set to close on December 6, 2022. Proceeds will be directed towards general corporate purposes, including repaying outstanding debts related to its acquisition of Aerie Pharmaceuticals, Inc. The notes will be issued by Alcon Finance Corporation and guaranteed by Alcon.
Alcon has successfully completed its acquisition of Aerie Pharmaceuticals for approximately $930 million. This acquisition strengthens Alcon's position in the $20 billion global ophthalmic pharmaceutical market, enhancing its product offerings with Rocklatan and Rhopressa, and adding AR-15512, a Phase 3 dry eye candidate. The deal will leverage Alcon’s commercial capabilities and expand its research and development expertise, supporting future growth. Alcon aims to fully integrate Aerie into its operations, building on previous acquisitions to enhance its ophthalmic pharmaceutical portfolio.
Alcon reported third quarter 2022 sales of $2.1 billion, reflecting a 2% increase year-over-year and a 9% rise in constant currency. Diluted earnings per share were $0.23, while core earnings per share were $0.50, down 7% on a reported basis but up 14% in constant currency. The updated 2022 outlook expects net sales between $8.5 billion and $8.7 billion, with a core operating margin tightening to 18.0%-18.5%. Challenges include foreign currency impacts and supply chain issues. The acquisition of Aerie Pharmaceuticals is anticipated to close in Q4 2022.
Summary not available.
Alcon (NYSE: ALC) has announced the launch of the Clareon Toric intraocular lens, designed for U.S. cataract patients with astigmatism, featuring advanced stability technology. This product completes the Clareon Collection, which includes various IOL options. Additionally, Alcon will showcase its Fidelis Virtual Reality Surgical Simulator and patient engagement tools at the upcoming AAO 2022 conference in Chicago. Studies presented will highlight the effectiveness and patient satisfaction associated with Alcon's products, supporting their commitment to innovative eye care solutions.
Alcon has announced a definitive merger agreement to acquire Aerie Pharmaceuticals for approximately $770 million. The transaction is expected to enhance Alcon's capabilities in the $20 billion global ophthalmic pharmaceutical segment by adding products like Rocklatan® and Rhopressa®. The acquisition is anticipated to be accretive to Alcon's core diluted EPS in 2024. Aerie's glaucoma franchise net product revenue is projected at $130-140 million for 2022, with the transaction expected to close in Q4 2022, pending shareholder and regulatory approvals.
Alcon reported strong second quarter 2022 sales of $2.2 billion, a 5% increase from the previous year, and a significant 10% rise in constant currency. Though diluted earnings per share fell 3% to $0.30, core diluted EPS rose 13% to $0.63. The company's outlook for the full year was updated to net sales between $8.6 to $8.8 billion, reflecting consistent core operating margins but reduced expectations for core diluted EPS growth. Despite challenges from currency fluctuations, Alcon remains focused on new products and profitability improvements.
Alcon has launched a new campaign featuring Cooper Kupp to promote Pataday Once Daily Relief Extra Strength, an over-the-counter solution for eye allergies. Kupp shares his own experiences battling eye allergies, emphasizing the product's effectiveness in providing 24-hour relief with just one drop. Approximately 66 million Americans suffer from ocular allergies, yet only 9 million use allergy eye drops. The campaign aims to raise awareness of Pataday's benefits through multimedia content and partnerships with social media influencers, encouraging allergy sufferers to seek relief.
Alcon Inc. (NYSE: ALC) announced a public offering of EUR 500 million in 2.375% senior notes due 2028. The offering will be conducted by Alcon Finance B.V., a wholly-owned subsidiary, and guaranteed by Alcon Inc. The notes are set to close on May 31, 2022, pending customary conditions. Proceeds will be used for general corporate purposes, including refinancing existing debt. The notes will also be listed on the Luxembourg Stock Exchange's Euro MTF.
Alcon, a leader in eye care, has announced the acquisition of EYSUVIS® and INVELTYS® eye drops from Kala Pharmaceuticals for an upfront payment of $60 million. EYSUVIS, approved for treating acute dry eye disease, complements Alcon's Systane family of products, enhancing treatment options for over 30 million affected individuals in the U.S. This strategic move is expected to strengthen Alcon's position in the growing dry eye category and is anticipated to close in Q3 2022, pending regulatory approval. 2021 revenues for EYSUVIS and INVELTYS were $6.3 million and $4.9 million, respectively.